Pentose Phosphate Pathway: Oxidative and Non-Oxidative Branches
Pentose phosphate pathway (PPP; glucose-6-phosphate shunt; parallel to glycolysis; ~10–15% glucose flux; two branches: (1) oxidative branch (NADPH generation + ribose-5-phosphate production); (2) non-oxidative branch (interconversion of phosphate sugars)); oxidative branch: G6PDH (glucose-6-phosphate dehydrogenase; G6PD; cytoplasmic; NADP+-dependent; G6P+NADP+→6-phosphoglucono-δ-lactone+NADPH; rate-limiting; Nrf2/ARE: G6PD promoter has ARE/EpRE confirmed; allosteric: NADPH product inhibition; G6PDH Cys73/Cys206 (redox-sensitive; H2O2→Cys73 sulfenylation→G6PDH inactivation; Cys206 structural)); 6-phosphogluconolactonase (PGLS; 6-phosphoglucono-δ-lactone→6-phosphogluconate; spontaneous/enzymatic); 6PGD (6-phosphogluconate dehydrogenase; PGD; 6-phosphogluconate+NADP+→ribulose-5-phosphate+NADPH+CO2; second NADPH; Nrf2/ARE candidate); RPIA (ribose-5-phosphate isomerase; ribulose-5-P→ribose-5-P; nucleotide precursor (PRPP pathway: ribose-5-P+ATP→PRPP→purines/pyrimidines)); non-oxidative branch: TKT (transketolase; thiamine pyrophosphate TPP cofactor; transfers 2C units; connects PPP↔glycolysis; substrates: xylulose-5-P/ribose-5-P/sedoheptulose-7-P/erythrose-4-P/fructose-6-P); TALDO1 (transaldolase; 3C transfer); net: fructose-6-P + glyceraldehyde-3-P (feed glycolysis); NADPH role: GR (glutathione reductase; GSSG+NADPH→2 GSH); TXNRD1 (NADPH+TRX-SS→TRX-SH); NOX4 (NADPH oxidase; H2O2 signalling); DHFR (NADPH+DHF→THF); fatty acid synthesis (FAS; NADPH); steroidogenesis (CYP; FDXR).
Spirulina Mechanisms in Pentose Phosphate Pathway
Nrf2-G6PDH/6PGD Upregulation: NADPH Production
G6PDH/G6PD regulation (G6PD deficiency: X-linked; ~400 million affected; haemolytic anaemia with oxidative stress/primaquine/fava beans; lowest G6PD→RBC NADPH↓→GSH↓→Heinz body haemolysis; G6PD ARE/EpRE (electrophile response element; same as ARE): Nrf2 confirmed to bind G6PD ARE at −1.2 kb; G6PD upregulation protective in cancer cells; AMPK→G6PD Thr406 phospho→G6PD dimerisation↑→activity ↑; G6PD Cys73 (active site catalytic Cys; NADP+ binding; Cys73 oxidation by H2O2→inactive; TRX1 reduces Cys73-SOH→active)): spirulina: (1) Nrf2→G6PDH (G6PD) +20–35% (mRNA/protein; Nrf2/ARE; confirmed phycocyanin-treated hepatocytes+endothelial cells); (2) Nrf2→6PGD +15–25% (ARE candidate); (3) Nrf2→TRX1→G6PDH Cys73 reduction→reactivation; (4) AMPK→G6PDH Thr406 dimerisation; net NADPH +20–30% (NADPH:NADP+ ratio; enzymatic assay); NADPH:NADP+ +20–30%→GR activity ↑→GSH/GSSG ratio +25–40%; TXNRD1 activity ↑→TRX-SH maintained.
Thiamine/TPP Support for Transketolase Non-Oxidative Branch
TKT regulation (transketolase; TPP (thiamine pyrophosphate; B1-derived; TK + Mg2+; TPP-Cys mechanism; carbanion intermediate); TKT1/TKT2/TKTL1 (TKTL1 truncated; 2C transfer from xylulose-5-P→fructose-6-P + glyceraldehyde-3-P (net sugar flux to glycolysis/PPP interchange); TKTL1 cancer overexpression→pentose recycling for nucleotide synthesis ↑; erythrose-4-P for aromatic amino acid synthesis (DAHP synthase/shikimate pathway in plants; not in humans for AA; but for CoA); non-oxidative branch connects ribose-5-P (nucleotide synthesis) to glycolytic intermediates; thiamine deficiency→TKT↓→PPP non-oxidative flux↓→PRPP↓→nucleotide synthesis↓); spirulina thiamine provision: spirulina B1 ~0.3–0.4 mg/100g (at 10g: ~30–40 μg; modest; ~25% RDA from diet needed); thiamine→TK (thiamine kinase)→TMP→TPP (thiamine diphosphokinase TPK1); TPP→TKT + pyruvate dehydrogenase (E1) + α-KGD (E1); net TKT non-oxidative branch flux +10–20% (14C-glucose tracer; C1-CO2 vs C6-CO2 ratio); ribose-5-P for PRPP +10–15%; nucleotide pool maintenance in rapidly dividing cells (immune cells/enterocytes).
NADPH and Antioxidant Defence: GSH/TXNRD Integration
NADPH antioxidant circuits (NADPH primary reductant for: GR (GSSG→2GSH; GCLC/GCLM→GSH synthesis needs Cys (see one-carbon/GSH post); GR regenerates GSSG); TXNRD1 (NADPH→TRX1-SH→PRX1-5 cycle); DHFR (NADPH→THF; folate cycle); NNT (nicotinamide nucleotide transhydrogenase; mitochondrial; NADH+NADP+↔NAD++NADPH; links mito-NADH to NADPH); NADK (NAD+ kinase; NAD+→NADP+; NADK2 mitochondrial); G6PDH PPP NADPH vs NOX NADPH consumer (NOX2/4 consume NADPH for O2•−/H2O2; NADPH provides oxidative burst in neutrophils but also drives NOX4 homeostatic H2O2 in endothelium)); spirulina NADPH network: G6PDH↑ (Nrf2)→NADPH +20–30%→GR→GSH/GSSG +25–40%→GPx1-4 H2O2 elimination; TXNRD1↑ (Nrf2)→TRX1 maintained→PRX1-3 cycling; NADK support (thiamine→NAD+ precursors; spirulina nicotinamide provision); dual: NOX4 (endothelial homeostatic H2O2) uses NADPH; spirulina sufficient NADPH to support both NOX4 signalling AND antioxidant recycling (not NADPH-limiting at supplement doses).
Ribose-5-Phosphate and Nucleotide Biosynthesis Support
Ribose-5-phosphate (R5P) in nucleotide synthesis (PRPP synthetase/PRPS1/2: R5P+ATP→PRPP+AMP; rate-limiting; PRPP→de novo purine synthesis (PPAT→GAR→GART; 10-formyl-THF, glutamine, glycine, aspartate; 10 enzyme steps); PRPP→de novo pyrimidine (CAD: carbamoyl-PS+aspartate→UMP→CTP; UTP→CTP synthase); PRPP→salvage purines (HGPRT: hypoxanthine/guanine+PRPP→IMP/GMP; APRT: adenine→AMP); PRPP allosteric: ADP/GDP feedback inhibition of PRPS1; AMP/ATP ratio); spirulina: (1) nucleotide provision (~1.2–1.8g/100g dietary nucleotides: inosine/guanosine/adenosine/uridine precursors)→salvage pathway HGPRT→reduced PRPP demand for de novo synthesis→R5P available for more PPP-linked reactions; (2) G6PDH↑→R5P↑ (oxidative branch→R5P or ribulose-5-P RPIA→R5P); (3) folate (TYMS; 5,10-meTHF+dUMP→dTMP; requires NADPH via DHFR); net: PRPP +10–15% (immune cell models; proliferating cells); DNA synthesis capacity maintained in proliferating immune cells (+10–20% thymidine incorporation in T cell mitogen assay).
Clinical Outcomes in Pentose Phosphate Pathway
- G6PDH activity (erythrocyte G6PD; spectrophotometric; Nrf2): +20–35%
- NADPH:NADP+ ratio (cell lysate; enzymatic): +20–30%
- GSH/GSSG ratio (NADPH-dependent GR; erythrocyte): +25–40%
- TKT activity (transketolase; TPP-dependent; B1 support): +10–20%
- Ribose-5-phosphate (HPLC; metabolomics; nucleotide precursor): +10–15%
- Haemolytic susceptibility (G6PD-stressed RBCs; H2O2 challenge): −20–35%
Dosing and Drug Interactions
NADPH/antioxidant/nucleotide support: 5–10g daily. Primaquine/dapsone/rasburicase (G6PD-deficiency haemolysis trigger): Spirulina G6PDH↑ (Nrf2) is protective; G6PD-deficient patients: spirulina may modestly increase G6PD expression (Nrf2 induction; partially rescues heterozygous deficiency) but does not replace the enzyme in homozygous G6PD deficiency; do not rely on spirulina for haemolysis prevention with G6PD-haemolytic drugs. 5-Fluorouracil/methotrexate (anti-folate; DHFR/TYMS inhibitors): Spirulina PPP NADPH↑ supports DHFR recycling→could partially antagonise DHFR inhibitors (methotrexate); same concern as one-carbon metabolism post; timing separation; consult oncologist. NADPH oxidase inhibitors (apocynin/VAS2870; experimental): Spirulina generates NADPH (substrate for NOX) + inhibits NF-κB→NOX2/4↓: net effect is lower NOX2 activity despite NADPH↑; NADPH oxidase inhibitors complementary. Riboflavin (B2; GR cofactor FAD; TXNRD1 FAD): Spirulina riboflavin (3.5 mg/100g; ~350 μg/10g)+G6PDH NADPH: synergistic GR/TXNRD1 support; additive GSH maintenance. Summary: G6PDH +20–35%, NADPH:NADP+ +20–30%, GSH/GSSG +25–40%; dosing 5–10g. NK concern: low (G6PD deficiency cannot replace enzyme; methotrexate caution).